Friday, 27 Mar 2020

Biologic/Novel Rx

Date Typesort ascending Title Save
13 Mar 2017 Social Review of severe alopecia areata 90pts Rx w/ Xeljanz: 20% nearly total regrowth, 58% >50% regrowth,77% some regrowth https://t.co/8BZwOqevct
07 Sep 2017 Social In 10yrs MTX/biologic use increased (40%/1.7% to 64%/27%) & rate of ortho surgery dropped (72 to 51/1000 pts in 2014 https://t.co/IE72n2YMPB
31 Jul 2018 Social EMA's CHMP has recommended approval of the IL-23 inhibitor tildrakizumab (Ilumetri, Almirall) for adults with moderate - severe plaque psoriasis. (Based on reSURFACE1 and reSURFACE2 RCTs w/ >80% PASI 75 responses. https://t.co/Qm0qIgAJ2G
15 Feb 2020 Social Finch 3 trial in MTX naive pts shows that mono Rx FIL 200=MTX mono for ACR20 but FIL200 superior for ACR50/70. 200mg works faster with more big responders early. Drs. Fleischman/Genovese at #RWCS2020 @RWCSmtg https://t.co/msgB6DS5cl
08 Jun 2016 Social Is there enough data to support a non-TNFi biologic as the 1st choice? Dr. Janet Pope says the data clearly says so https://t.co/Ai5izsTDN8
16 Nov 2016 Social RT @rachelthuston: TCZ for clinical remission in GCA but doesn't fully suppress MR signals of vessel inflammation #ACR16 @RheumNow https://…
14 Apr 2017 Social How will new BIOSIMILAR biologic drugs affect PATIENTS - Make Your views count in a Patient survey; vote at>> https://t.co/ZhM9MiDCd7
23 Oct 2015 Social Pretreatment CRP or IL-6 levels are not predictive of responses to tocilizumab https://t.co/IOQGWOGGQA
09 May 2018 Social AbbVie Submits Biologics License Application to FDA for Risankizumab (IL-23 Mab) for Moderate to Severe Plaque Psoriasis https://t.co/4lq3xKc6T1
25 Jul 2019 Social FDA has approved Ruxience (rituximab-pvvr; Pfizer), a biosimilar to Rituxan for use in NHL, CLL, granulomatosis w/ polyangiitis (GPA) & microscopic polyangiitis;(NOT RA) THis is the 2nd RTX biosimilar. https://t.co/GuVG6S980j
22 Sep 2015 Social OCTAVE studies shows tofacitinib 10 mg bid to be effective in treating moderate to severe ulcerative colitis http://t.co/MbdSUymAji
10 May 2017 Social Responses to Orencia may be dependent on baseline memory B cells (CD38+ CD27+) https://t.co/zro040Y54W
07 Nov 2017 Social RT @philipcrobinson: New Jak-1 selective inhibitor ABT-494 doesn’t look too bad #ACR17 @RheumNow https://t.co/sAHVqJr31a
27 Nov 2015 Social RCT shows Hidradenitis suppurativa pts respond well to anakinra (esp after wk 8) w/ less IFN and increased IL-22 https://t.co/OfndT569gt
23 Oct 2018 Social RT @ArthurRheum: Another Adalimumab biosimilars is coming... similar efficacy and immunogenicity as original @RheumNow #ACR18 https://t.co/…
13 Jun 2018 Social RT @philipcrobinson: A phase IIB study of UCBs new anti-IL-17 drug bimekizumab that neutralises both IL17 A and F showed good results, can’…
16 Jan 2017 Social Baricitinib decision by the FDA extended from Jan 2017 by another 3 mos for FDA to review major amendment to NDA https://t.co/tMi3llwWZw
23 May 2017 Social FDA approves Actemra as1st approved drug to treat Giant Cell Arteritis. See RheumNow report. https://t.co/73UieZpbn1 https://t.co/HjUzi0H6OL
13 Nov 2019 Social RT @Janetbirdope: Tofa is not different from bDMARDs in Corrona for cancer and deaths. reassuring and adds to growing safety data #ACR #ACR…
25 Feb 2016 Social How to manage patients who worry, wont do & negatively inclined re:health/meds - the negative narrator in your head https://t.co/KEeVcWVedr